Relypsa Inc (RLYP)

31.99
0.02 0.06
Prev Close 31.97
Open 31.99
Day Low/High 31.97 / 32.04
52 Wk Low/High 10.26 / 32.12
Volume 2.43M
Avg Volume 3.23M
Exchange
Shares Outstanding 44.88M
Market Cap 1.44B
EPS -4.40
Div & Yield N.A. (N.A)

Latest News

3 Biotech-Investing Mistakes to Avoid

3 Biotech-Investing Mistakes to Avoid

These are the biggest errors that I've made over the years.

Short Interest Declines 42.5% For RLYP

Short Interest Declines 42.5% For RLYP

The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 6,916,160 share decrease in total short interest for Relypsa, Inc , to 9,368,893, a decrease of 42.47% since 07/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs

Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

RELYPSA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces The Investigation Of Relypsa, Inc. (RLYP) Over The Proposed Sale Of The Company To Galenica Group

RELYPSA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces The Investigation Of Relypsa, Inc. (RLYP) Over The Proposed Sale Of The Company To Galenica Group

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Relypsa, Inc.

These 4 Stocks Could See Negative Catalysts From Earnings -- but What Do the Charts Say?

These 4 Stocks Could See Negative Catalysts From Earnings -- but What Do the Charts Say?

Morgan Stanley believes these stocks will have negative earnings catalysts, but how does the technical analysis stack up?

RELYPSA, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Believe The Acquisition By Galenica May Be Unfair To Shareholders

RELYPSA, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Believe The Acquisition By Galenica May Be Unfair To Shareholders

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Relypsa, Inc.

Synergy Pharma Offers Lots of Synergies

Synergy Pharma Offers Lots of Synergies

I expect Allergan or another player to bid for SGYP soon.

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Relypsa Stock Surges on $1.53 Billion Galenica Takeover Offer

Relypsa Stock Surges on $1.53 Billion Galenica Takeover Offer

Shares of Relypsa surged on news of a takeover by Galenica, the owner of Switzerland's biggest pharmacy network.

4 Small-Cap Biotechs With Big Stories to Tell

4 Small-Cap Biotechs With Big Stories to Tell

Watch these names as stability returns to the sector.

Relypsa Finally Finds Buyer, but Potential Seen For Rival Bid

Relypsa Finally Finds Buyer, but Potential Seen For Rival Bid

Shares of Relypsa are rallying after the company announced it has agreed to be acquired by Galenica Group in a $1.53B deal.

Relypsa (RLYP) Stock Surging on $1.5 Billion Acquisition by Galencia

Relypsa (RLYP) Stock Surging on $1.5 Billion Acquisition by Galencia

Relypsa (RLYP) stock is up in early morning trading on Thursday after Galenica agreed to purchase the biotech for $1.53 billion.

Morning Movers: GM, JOY, RLYP, BIIB

Morning Movers: GM, JOY, RLYP, BIIB

General Motors crushed Wall Street earnings estimates before the opening bell.

Galenica to Buy Relypsa for $1.53 Billion

Galenica to Buy Relypsa for $1.53 Billion

The Swiss buyer will gain better U.S. access and drugs including Veltassa, which treats high blood potassium levels.

Market’s Overbought Condition Is Standard Fare

After a big run-up, the market behaved in typical fashion -- no damage done.

RLYP: Insiders vs. Shorts

RLYP: Insiders vs. Shorts

The most recent short interest data was recently released for the 06/30/2016 settlement date, and Relypsa, Inc is one of the most shorted stocks of the Russell 3000, based on 6.01 "days to cover" versus the median component at 4.51. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.